Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Deloitte
Baxter
QuintilesIMS
Farmers Insurance
Julphar
Federal Trade Commission
Accenture
Express Scripts

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NESIRITIDE RECOMBINANT

« Back to Dashboard

Clinical Trials for Nesiritide Recombinant

Trial ID Title Status Sponsor Phase Summary
NCT00075179 Natrecor in Pulmonary Hypertension Terminated M.D. Anderson Cancer Center Phase 4 The goal of this clinical research study is to learn if the drug nesiritide (Natrecor) is effective in lowering the pressure in your lungs. The primary objective of this study is to establish that Nesiritide (Natrecor) is effective in reducing pulmonary hypertension (PHTN) acutely as measured by a 20% reduction in the mean pulmonary arterial (PA) pressure. The secondary objectives will include: improvement in pulmonary vascular resistance (PVR), patient symptoms, exercise tolerance, frequency of toxicity, and surgeon's willingness to proceed with operation.
NCT00083772 Use of Nesiritide in the Management of Acute Diastolic Heart Failure Terminated M.D. Anderson Cancer Center Phase 4 Primary objective is to assess the effect of nesiritide in decreasing left ventricular (LV) filling pressure, defined as pulmonary artery capillary wedge pressure (PCWP) in a group of patients admitted with acute diastolic heart failure. Secondary objectives include: improvement in symptoms, exercise tolerance, improvement in Doppler diastolic filling parameters in patients with diastolic heart failure.
NCT00091520 A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart Failure Completed Scios, Inc. Phase 2 The purpose of this study is to evaluate the efficacy and safety of Nesiritide administered as serial infusions to heart failure (HF) patients in the outpatient setting.
NCT00110201 The Use of Nesiritide in Thoracic Aneurysm Repair to Prevent Acute Renal Failure Unknown status Ejaz, Abulate A, MD Phase 3 The purpose of this trial is to study the use of nesiritide in thoracic aneurysm repair to prevent acute renal failure. The study hypothesis: Nesiritide, given prophylactically prior to surgery may prevent acute renal failure requiring dialysis and/or decrease mortality.
NCT00119691 Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction Completed Scios, Inc. Phase 2 The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.
NCT00119691 Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction Completed Brigham and Women's Hospital Phase 2 The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nesiritide Recombinant

Condition Name

Condition Name for Nesiritide Recombinant
Intervention Trials
Congestive Heart Failure 13
Heart Failure, Congestive 12
Heart Failure 8
Hypertension 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nesiritide Recombinant
Intervention Trials
Heart Failure 39
Renal Insufficiency 7
Hypertension 6
Cardiomyopathies 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nesiritide Recombinant

Trials by Country

Trials by Country for Nesiritide Recombinant
Location Trials
United States 89
Canada 7
China 3
Norway 2
Australia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nesiritide Recombinant
Location Trials
Minnesota 14
Florida 7
Massachusetts 6
Texas 6
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nesiritide Recombinant

Clinical Trial Phase

Clinical Trial Phase for Nesiritide Recombinant
Clinical Trial Phase Trials
Phase 4 13
Phase 3 12
Phase 2 11
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nesiritide Recombinant
Clinical Trial Phase Trials
Completed 32
Terminated 15
Withdrawn 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nesiritide Recombinant

Sponsor Name

Sponsor Name for Nesiritide Recombinant
Sponsor Trials
Scios, Inc. 26
Mayo Clinic 9
National Heart, Lung, and Blood Institute (NHLBI) 5
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nesiritide Recombinant
Sponsor Trials
Other 53
Industry 31
NIH 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Harvard Business School
Farmers Insurance
Fuji
Argus Health
Cerilliant
Julphar
Accenture
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.